Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy

Melanoma Research

Volumn 24, Issue 5, 2014, Pages 501-503

  Uribe, Pablo ^a,d   Anforth, Rachael M ^a,b   Kefford, Richard F ^a,b,c   Fernandez Peñas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Acne; Acneiform eruptions; Dabrafenib; Metastatic melanoma; Trametinib

Indexed keywords

B RAF KINASE; CEFALEXIN; CHLORHEXIDINE; DABRAFENIB; PREDNISONE; TRAMETINIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CORTICOSTEROID; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ACNE; ADULT; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG WITHDRAWAL; FATALITY; FEMALE; FEVER; HUMAN; LYMPH NODE METASTASIS; METASTATIC MELANOMA; PRIORITY JOURNAL; RETREATMENT; RIGOR; CHEMICALLY INDUCED; COMPLICATION; DISEASE COURSE; DRUG ADMINISTRATION; GENETICS; MELANOMA; METASTASIS; MUTATION; SKIN NEOPLASMS; TIME; TREATMENT OUTCOME;

ACNEIFORM ERUPTIONS; ADRENAL CORTEX HORMONES; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FATAL OUTCOME; FEMALE; FEVER; HUMANS; IMIDAZOLES; MELANOMA; MUTATION; NEOPLASM METASTASIS; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926118082     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000096     Document Type: Article

References (10)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
2. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-1901.
3. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703.
4. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
5. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013;14:e11-e18.
6. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:773-781.
7. Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012;167:1153-1160.
8. Zimmer L, Vaubel J, Livingstone E, Schadendorf D. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges 2012;10:475-486.
9. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812.
10. Schad K, Baumann Conzett K, Zipser MC, Enderlin V, Kamarashev J, French LE, Dummer R. Mitogen-activated protein/extracellular signalregulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010;16:1058-1064.